XHXiaodong Huang

Xiaodong Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaodong Huang has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Ting Zhan

    Department of Gastroenterology, Tongren Hospital of Wuhan University (WuHan Third Hospital), Wuhan, China

    12 shared publications
  • Xia Tian

    Department of Gastroenterology, Tongren Hospital of WuHan University (WuHan Third Hospital), Wuhan 430060, China

    11 shared publications
  • Xiaoli Chen

    Department of Gastroenterology, Tongren hospital of WuHan University(WuHan Third Hospital), Wuhan, China

    10 shared publications
  • Zheng Han

    Department of Gastroenterology, Tongren Hospital of WuHan University(WuHan Third Hospital), Wuhan 430060, China

    10 shared publications
  • Jie Tan

    Department of Gastroenterology, Tongren Hospital of WuHan University(WuHan Third Hospital), Wuhan 430060, China

    8 shared publications
  • Meng Liu

    Department of Gastroenterology, Tongren hospital of WuHan University(WuHan Third Hospital), Wuhan, China

    8 shared publications

Latest Publications

  • Open Access

    Emerging role of ETV4 in colorectal cancer: from molecular mechanisms to clinical implications

    by Yuanbin Liu, Yiyun Wang, Min Huang, Xia Tian, Xiaodong Huang

    ETV4 (ETS-transformation-specific variant 4) is a member of the ETS transcription factor family that has been extensively studied for its oncogenic functions in cancers. Here, we summarize the role and mechanisms of ETV4 in cancer biology, with a particular focus on colorectal cancer (CRC), as well as its biomarkers and therapeutic potential. As a transcription factor, ETV4 regulates the expression of target genes by recognizing the GGA(A/T) core conserved sequence. It is frequently overexpressed in pan-cancer, where its overexpression associated with poor prognosis. Upon activation by oncogenic signaling pathways (e.g., MAPK, PI3K/Akt, and WNT), ETV4 transcriptionally regulates downstream genes to promote tumor cell proliferation, invasion, migration, epithelial-mesenchymal transition (EMT), chemoresistance, metabolic reprogramming, and immune evasion. It also form a vicious positive feedback loop that continuously activates oncogenic signaling. In CRC, ETV4 is overexpressed, correlating with advanced disease, lymph node metastasis, and poor prognosis. Upon activation by oncogenic signals, ETV4 directly activate target genes (such as matrix metalloproteinases) to mediate adenoma-to-adenocarcinoma progression, proliferation, EMT, ferroptosis, invasion, metastasis, metabolic reprogramming, and tumor microenvironment remodeling in CRC. ETV4 also forms transcriptional complexes with certain epigenetic factors, such as miRNAs and p300. Moreover, ETV4 is a promising biomarker for CRC diagnosis, prognosis, and adenoma-to-adenocarcinoma progression. Targeting ETV4 or its upstream pathways represents a potential therapeutic strategy for CRC. However, there are still many unresolved issues in current research. For example, the role of ETV4 in immune evasion and tumor microenvironment remodeling remains at the descriptive stage, and the specific mechanisms by which it regulates immune cell recruitment have not yet been elucidated. Future efforts include utilizing multi-omics approaches to elucidate the mechanisms by which ETV4 shapes the CRC microenvironment and exploring the application prospects in tumor immunotherapy.

  • Open Access

    The RASSF1C-HIF-1α axis drives macrophage lipid metabolism to promote pancreatic cancer

    by Ting Zhan, Min Huang, Mengge Chen, Wei Chen, Yiyun Wang, Xiaoli Chen, Yanli Zou, Meng Liu, Qingxi Zhu, Xia Tian, et al.

    Pancreatic adenocarcinoma (PAAD) has a poor prognosis. Its microenvironment is closely associated with tumor progression and immune evasion. This study combines single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) to reveal the critical role of tumor-associated macrophages (TAMs) in PAAD. Ras association domain family member 1 C (RASSF1C) is significantly upregulated under hypoxia, enhancing glycolysis by promoting the Warburg effect. This generates lactate and contributes to acidification of the tumor microenvironment (TME). Lactate activates TAMs and reprograms their lipid metabolism, promoting PAAD migration and invasion. Further investigation demonstrated that lactate suppressed ubiquitin-fold modifier 1 ligating enzyme 1 (UFL1) protein levels in macrophages, thereby weakening the protective effect of UFL1-mediated interferon regulatory factor 7 (IRF7) UFMylation. This suppression led to enhanced K48-linked ubiquitination of IRF7 and accelerated proteasomal degradation, ultimately reducing IRF7 stability and impairing lipid metabolic functions in macrophages. Additional mechanistic evidence showed that UFL1-UFMylation axis maintains IRF7 homeostasis by counteracting K48-linked ubiquitin-mediated degradation. Moreover, immunohistochemical (IHC) validation using tissue microarrays from 20 human pancreatic ductal adenocarcinoma (PDAC) specimens revealed that the overall expression of RASSF1C and hypoxia-inducible factor-1 alpha (HIF-1α) was higher than that of UFL1 and IRF7. RASSF1C expression was significantly positively correlated with HIF-1α and negatively correlated with UFL1 and IRF7. Clinicopathological correlation analysis further showed that high RASSF1C expression was associated with poor differentiation and advanced TNM stage, whereas low UFL1 and IRF7 expression was associated with lymph node metastasis. Collectively, this study demonstrated that the hypoxia-RASSF1C-HIF-1α axis reshaped TAM function through lactate-mediated immunometabolic regulation and promoted PAAD progression by inhibiting UFL1-mediated IRF7 UFMylation, thereby reducing IRF7 stability. These findings identify potential therapeutic targets for combined metabolic and immune interventions in PAAD.


  • ILF3 mediates lipid metabolism to promote pancreatic cancer development by regulating CPT1A-activated PPARa signaling pathway

    by Ting Zhan, Mengge Chen, Qingxi Zhu, Meng Liu, Jie Tan, Xiaoli Chen, Jiaxi Liu, Zheng Han, Yanli Zou, Xia Tian, et al.


  • Open Access

    Demystifying the Role of Histone Demethylases in Colorectal Cancer: Mechanisms and Therapeutic Opportunities

    by Yuanbin Liu, Min Huang, Xia Tian, Xiaodong Huang

    Histone demethylases (HDMs) play a pivotal role in colorectal cancer (CRC) progression through dynamic epigenetic regulation. This review summarizes the role and therapeutic potential of HDM in CRC. HDMs primarily target lysine (K) for demethylation (lysine demethylase, KDM). The KDM family is divided into the lysine-specific demethylase family and the Jumonji C domain-containing family. HDMs play complex roles in CRC cell proliferation, invasion, migration, stemness, epithelial–mesenchymal transition, immune response, and chemoresistance through epigenetic regulation of different histone demethylation sites. Increasing evidence suggests that KDM may interact with certain factors and regulate CRC tumorigenesis by modulating multiple signaling pathways and affecting the transcription of target genes. These processes may be regulated by upstream genes and thus form a complex epigenetic regulatory network. However, the potential roles and regulatory mechanisms of some HDMs in CRC remain understudied. Preclinical studies have revealed that small-molecule inhibitors targeting HDM impact the activity of specific genes and pathways by inhibiting specific HDM expression, thereby reshaping the tumorigenic landscape of CRC. However, the clinical translational potential of these inhibitors remains unexplored. In conclusion, HDMs play a complex and critical role in CRC progression by dynamically regulating histone methylation patterns. These HDMs shape the malignant behavior of CRC by influencing the activity of key pathways and target genes through epigenetic reprogramming. Targeting HDM may be a promising direction for CRC treatment. Further exploration of the role of specific HDMs in CRC and the therapeutic potential of HDM-specific inhibitors is needed in the future.


  • Open Access

    ILF3 inhibits p-AMPK expression to drive non-alcoholic fatty liver disease progression

    by Ting Zhan, Jia-Xi Liu, Min Huang, Ming-Tao Chen, Xiao-Rong Tian, Xiu-Lin Yang, Jie Tan, Yan-Li Zou, Zheng Han, Wei Chen, et al.

    BACKGROUND Non-alcoholic fatty liver disease (NAFLD) is a disease of increasing global prevalence and an important risk factor for the development of insulin resistance, type 2 diabetes, non-alcoholic steatohepatitis and hepatocellular carcinoma, but the pathogenesis is not clear. The aim of this study was to explore the role of ILF3 in NAFLD. AIM To investigate the molecular processes through which ILF3 facilitates the advancement of NAFLD by inhibiting the expression of p-AMPK. This exploration seeks to provide new insights into the etiology of NAFLD and evaluate the potential of ILF3 as a diagnostic marker and potential treatment focus for future interventions. METHODS In vitro and in vivo experiments were conducted using HepG2 cells and NAFLD animal models. The effects of ILF3 knockdown on lipid synthesis and triglyceride (TG) secretion were examined by analyzing the expression levels of p-AMPK. Additionally, the roles of ILF3 and the AMPK signaling pathway were verified using techniques such as Western blotting, quantitative reverse transcription PCR, Oil Red O staining, and immunohistochemistry. RESULTS Investigations revealed an increase in ILF3 Levels within both HepG2 cells and animal models of NAFLD, concurrently with a decrease in p-AMPK expression. Knocking down ILF3 activated the AMPK pathway, reducing lipid production and TG secretion in hepatocytes, thereby mitigating the advancement of NAFLD. CONCLUSION ILF3 promotes the evolution of NAFLD by inhibiting the expression of p-AMPK. The knockdown of ILF3 activates the AMPK signaling pathway, alleviating the severity of NAFLD. These findings underscore the function of ILF3 in the pathogenesis of NAFLD and demonstrate its viability as a treatment focus and diagnostic indicator.

  • Open Access

    Weight-adjusted waist index is positively and linearly associated with all-cause and cardiovascular mortality in metabolic dysfunction-associated steatotic liver disease: findings from NHANES 1999-2018

    by Weijie Liu, Xiulin Yang, Ting Zhan, Min Huang, Xiaorong Tian, Xia Tian, Xiaodong Huang

    Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease. Body mass index (BMI) is the most used obesity index but has important limitations. The weight-adjusted waist index (WWI) is a novel obesity metric and accurately reflects body composition. We explored the association of WWI with all-cause and cardiovascular disease (CVD) mortality in MASLD.Methods: Adult participants with MASLD were included from NHANES 1999-2018. WWI was calculated by dividing the waist circumference (WC) by the square root of body weight. MASLD was diagnosed by the presence of hepatic steatosis and at least one cardiometabolic risk factor in the absence of other causes of steatosis. A fatty liver index ≥60 suggested the presence of hepatic steatosis. Mortality data was obtained by prospectively linking to the National Death Index. Multivariate Cox proportional hazards regression analyses were used to explore these associations and multiple adjustment models were constructed including crude, partial, and fully adjusted models.Results: After adjusting for all covariates including BMI, WWI remained positively and linearly associated with all-cause and CVD mortality in MASLD (hazard ratios [HR] 1.247 and 1.218, respectively). Higher WWI was associated with a significantly increased risk of mortality (both p for trend <0.05). There was an “obesity paradox” between BMI and all-cause mortality in MASLD, with significantly lower all-cause mortality in those with overweight/obesity compared to normal BMI (HR 0.625 and 0.596, respectively, p for trend = 0.024), and no association between BMI and CVD mortality. Interaction analyses indicated that these associations were influenced by several demographic variables and disease status. Time-dependent receiver operating characteristic curves indicated that the predictive value of WWI for mortality in MASLD was higher than that of BMI, WC, and waist-to-height ratio across all follow-up durations.Conclusions: WWI was positively and linearly associated with all-cause and CVD mortality in MASLD, whereas BMI did not accurately reflect mortality risk. WWI provided the optimal predictive value for mortality compared to traditional obesity indicators. These findings emphasize the potential use of WWI as a novel obesity indicator for mortality risk assessment, stratification, and prevention in MASLD.


  • Open Access

    Single‐cell sequencing combined with spatial transcriptomics reveals that the IRF7 gene in M1 macrophages inhibits the occurrence of pancreatic cancer by regulating lipid metabolism‐related mechanisms

    by Ting Zhan, Yanli Zou, Zheng Han, XiaoRong Tian, Mengge Chen, Jiaxi Liu, Xiulin Yang, Qingxi Zhu, Meng Liu, Wei Chen, et al.

    Aim: The main focus of this study is to explore the molecular mechanism of IRF7 regulation on RPS18 transcription in M1‐type macrophages in pancreatic adenocarcinoma (PAAD) tissue, as well as the transfer of RPS18 by IRF7 via exosomes to PAAD cells and the regulation of ILF3 expression.Methods: By utilising single‐cell RNA sequencing (scRNA‐seq) data and spatial transcriptomics (ST) data from the Gene Expression Omnibus database, we identified distinct cell types with significant expression differences in PAAD tissue. Among these cell types, we identified those closely associated with lipid metabolism. The differentially expressed genes within these cell types were analysed, and target genes relevant to prognosis were identified. Flow cytometry was employed to assess the expression levels of target genes in M1 and M2 macrophages. Cell lines with target gene knockout were constructed using CRISPR/Cas9 editing technology, and cell lines with target gene knockdown and overexpression were established using lentiviral vectors. Additionally, a co‐culture model of exosomes derived from M1 macrophages with PAAD cells was developed. The impact of M1 macrophage‐derived exosomes on the lipid metabolism of PAAD cells in the model was evaluated through metabolomics analysis. The effects of M1 macrophage‐derived exosomes on the viability, proliferation, division, migration and apoptosis of PAAD cells were assessed using MTT assay, flow cytometry, EdU assay, wound healing assay, Transwell assay and TUNEL staining. Furthermore, a mouse PAAD orthotopic implantation model was established, and bioluminescence imaging was utilised to assess the influence of M1 macrophage‐derived exosomes on the intratumoural formation capacity of PAAD cells, as well as measuring tumour weight and volume. The expression of proliferation‐associated proteins in tumour tissues was examined using immunohistochemistry.Results: Through combined analysis of scRNA‐seq and ST technologies, we discovered a close association between M1 macrophages in PAAD samples and lipid metabolism signals, as well as a negative correlation between M1 macrophages and cancer cells. The construction of a prognostic risk score model identified RPS18 and IRF7 as two prognostically relevant genes in M1 macrophages, exhibiting negative and positive correlations, respectively. Mechanistically, it was found that IRF7 in M1 macrophages can inhibit the transcription of RPS18, reducing the transfer of RPS18 to PAAD cells via exosomes, consequently affecting the expression of ILF3 in PAAD cells. IRF7/RPS18 in M1 macrophages can also suppress lipid metabolism, cell viability, proliferation, migration, invasion and intratumoural formation capacity of PAAD cells, while promoting cell apoptosis.Conclusion: Overexpression of IRF7 in M1 macrophages may inhibit RPS18 transcription, reduce the transfer of RPS18 from M1 macrophage‐derived exosomes to PAAD cells, thereby suppressing ILF3 expression in PAAD cells, inhibiting the lipid metabolism pathway, and curtailing the viability, proliferation, migration, invasion of PAAD cells, as well as enhancing cell apoptosis, ultimately inhibiting tumour formation in PAAD cells in vivo. Targeting IRF7/RPS18 in M1 macrophages could represent a promising immunotherapeutic approach for PAAD in the future.


  • CXCL6 promotes the progression of NAFLD through regulation of PPARα

    by Yanli Zou, Ting Zhan, Jiaxi Liu, Jie Tan, Weijie Liu, Shasha Huang, Yisan Cai, Ming Huang, Xiaodong Huang, Xia Tian


  • Open Access

    Characterization of Procollagen-lysine, 2-oxoglutarate 5-dioxygenases as Therapeutic Targets in a Pan-Cancer Study

    by Weijie Liu, Jiaxi Liu, Junsheng Deng, Ting Zhan, Zheng Han, Jie Tan, Meng Liu, Mengge Chen, Xia Tian, Xiaodong Huang

    Background Certain members of the Procollagen-lysine 2-oxyglutarate 5-dioxygenase (PLOD) family have been identified to play a role in tumor metastasis and progression. Materials & Methods The association between PLOD expression and overall survival (OS) rates was assessed utilizing the Kaplan-Meier survival curve. The correlation between gene expression and patient OS rate was determined utilizing a univariate or multivariate Cox proportional hazards regression model or log-rank test to evaluate the difference in OS rates. The infiltration levels of stromal cells and immune cells in different tumors were analyzed utilizing the stromal-immune-ESTIMATE score. Results Our results showed that PLOD1, PLOD2, and PLOD3 were predominantly upregulated in cancer cells, and the expression of PLOD family members frequently correlated with the OS of cancer patients. All PLOD genes exhibited significant associations with immune infiltration subtypes, as well as different levels of stromal cell infiltration and tumor cell stemness. Furthermore, our research demonstrated that the PLOD gene might contribute to drug resistance in cancer cells. Conclusion Our study indicated that PLOD was primarily associated with more aggressive cancer characteristics and potentially contributed to tumor metastasis and tumorigenesis, leading to a poorer prognosis.